Search CommunityWalk:


Amulet Pharmaceuticals Inc

Rockville, MD, USA

Category: Drug Delivery

Used in the following map:

Maryland Biotech Industry Map

Amulet Pharmaceuticals Inc is a biotechnology company that focuses on developing safer and more effective high-value drugs by engineering nitric oxide release into well-established, commercially successful therapeutics. It was founded in 2001 by Robert Raulli.

Amulet Pharmaceuticals has developed a therapeutic technology, NORTECH(TM) for the treatment of gastrointestinal diseases. The company has also developed a safe method to deliver the nitric oxide topically to the affected tissues in the stomach and GI tract. Its nitric oxide delivery technology, NORTECH(TM) and AMU-301 delivers nitric oxide through a carbon-based (C-based) NONOate (Diazeniumdiolate) group in response to neutral and acidic pH. The company's primary area of focus is in the area of gastrointestinal disorders including: Gastroparesis, Obesity, Enteral feeding in critical care patients, Irritable bowel syndrome, Functional dyspepsia, Wounds, Diabetes therapeutics, Pain therapeutics and Glaucoma.

Amulet's compound, AMU-301, has a microporous hydrophobic polymer backbone where the acid-sensitive NONate groups sit deep in the polymer and are protected from the acidity of the stomach. AMU-301 can be used to treat other gastrointestinal conditions such as obesity, enteral feeding in critical care patients, irritable bowel syndrome, functional dyspepsia. AMU-301 delivers targeted nitric oxide throughout the GI tract. The polymer scaffold of AMU-301 is identical to the scaffold of the approved drug Cholestyramine USP which has a long history of safe clinical use. The same polymer scaffold is also used as a GRAS (generally regarded as safe by FDA) food additive.

Amulet has collaboration with several government and academic laboratories to identify novel IP to in-license as well as maintain access to the latest science and technology. It also has a collaboration agreement with NCI and share materials and data. The company has a collaboration agreement and a sub-contract with Georgetown University Medical Center to conduct research and animal studies in gastroparesis and agreements with several other leading universities.